believ like event year year
investor may ask consid
potenti upsid event downsid note
updat model price target new estim
vs previou line myl state
ep target least rais price target
note share outperform market
recent week ytd vs ytd
share under-perform past year
year year period maintain market perform rate
believ market current hope abl
obtain gener advair and/or gener restasi approv new
competit emerg copaxon epipen
us mix posit neg detail
note posit front like see mylan
continu make progress gener copaxon continu
gain share potenti larg market gener opportun
potenti approv gener advair restasi
neg believ face anoth potenti headwind
gener a/b rate epipen new copaxon gener emerg
believ teva provid new guidanc
assum one new gener copaxon entrant mid-
also believ gener sector rapid margin-
declin environ caution warrant updat
model includ chang base year dcf
increas mylan discount valu
line current bloomberg-deriv wacc
increas ev/ebitda termin multipl account
upcom catalyst sector averag
believ given gener drug industri margin declin
mylan lower earn guidanc investor take
cautiou approach im data continu show littl sign
relief gener manufactur three month roll averag
im data novemb includ exhibit
follow page show continu weak gener
busi sale trend volum
yoy compar yoy octob sale volum
yoy compar octob
midpoint ep guidanc repres declin
yoy know grow substanti
organ basi investor awar declin ep
midpoint come despit full year meda
close august launch gener copaxon
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
compani prioriti stock list
compani data secur llc estim reuter
believ like event year year investor may ask
consid potenti upsid downsid us mix
posit neg
copaxon like see continu gener copaxon launch gener copaxon
steadili grow share expect continu anoth gener compani
emerg approv real possibl addit neg
impact launch gener epipen believ face anoth potenti headwind
gener a/b rate epipen emerg believ like
previous model would garner share price discount copaxon
sale gener howev accord im data appear garner
approxim nrx know chang slowli overtim whether
step function higher start new year formulari coverag chang
addit know teva done price maintain share would assum
signific discount perhap even previous assum result
lower mylan revenu slightli account lower expect market share
point model vs previous
drop subsequ quarter vs previou base expect
advair gener advair wildcard know time know mani player
get approv know whether among player market format
previous estim would garner gener advair market assum
would discount believ like multipl player advair
billion brand us declin rapidli annual approxim
billion us expect advair market face approxim price declin
garner approxim market share
restasi said expect approv gener version allergan blockbust dri eye
treatment estim could garner gener restasi market
assum would discount time seem like compet
variou gener entrant outset model gener competit restasi
gener also continu believ gener sector rapid margin declin environ
caution warrant
tax recent investor confer state potenti impact tax reform expect
rel neutral compani chang estim tax rate time
dcf make slight chang dcf assumpt first given start
use month price target elimin discount increas mylan
discount valu line current bloomberg-deriv wacc
increas ev/ebitda termin multipl past sever year teva
use termin multipl believ valid argument higher
lower multipl posit side sector trade higher ev/ebitda valu sever
recent acquisit made substanti higher multipl addit sever
posit product develop recent launch gener copaxon potenti
big hit restasi advair other said reduc earn guidanc
substanti lead us believ earn risk higher averag
approv gener copaxon posit believ risk addit competit gener
copaxon well gener epipen high
liabil lower estim liabil billion million agre
million payment doj govern agenc relat epipen medicaid
drug rebat program maintain liabil dcf outstand litig
investig octob attorney gener state district columbia accus
compani subsidiari name medicin broad price fix scheme suit also target
rajiv malik presid execut director accord reuter found evid
price-fix compani employe vow defend vigor
rais price target note share outperform market
recent week ytd vs ytd howev believ share
like perform line market maintain market perform rate
share under-perform past year year year period
midpoint ep guidanc repres declin yoy know
grow substanti organ basi investor awar declin ep
midpoint come despit full year meda close august launch
gener copaxon octob
believ given gener drug industri margin declin mylan lower earn guidanc
investor take cautiou approach im data continu show littl sign relief
gener manufactur three month roll averag im data novemb includ exhibit
show continu weak gener busi sale trend volum
yoy compar yoy octob sale volum yoy compar
octob
im health secur llc
disclaim analysi independ arriv well fargo secur llc basi data
inform im respons relianc recipi either data analys thereof
factset secur llc estim
compani report secur llc estim
incom segment revenu north rest chg segment revenu north rest profit expens expens interest incom incom incom per
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like less favor prior
year gener compani may less polit cover go forward gener drug
penetr may alreadi peak epipen concentr sale profit govern risk
sec investig lawsuit integr risk tie meda deal
remain market perform believ face anoth potenti headwind gener a/b
rate epipen emerg believ like also believ gener sector
rapid margin-declin environ caution warrant
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
